Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BLOCK & KETCHUM LEAD O-T-C ISSUES IN JUNE; ZENITH PACES GENERIC ADVANCE

Executive Summary

Ketchum (up 3-1/8 to 22-1/2) and Block (up 3 to 35-1/2) led all issues in June on the Monthly "F-D-C" Index of O-T-C stock issues. Since April, Ketchum's stock has soared 6-5/8. The whslr's. market valuation is up 45% from the close of 1984, to $24.3 mil. With the current wave of acquisitions in the drug whsle. business, Ketchum issued a statement mid-month asserting there are no "undisclosed events" to justify the recent stock increase. Although 19 of the 38 stocks on the Index advanced, with 16 declining, and three unchanged, the O-T-C Composite lost ground for only the second time in 1985. The Index lost ground due to point-or-more losses by Cetus (1-1/2 to 10-3/4), Enzo (1-1/4 to 12-1/4), Nelson R&D (1-1/4 to 7); Natl. Patent (1-3/8 to 13-5/8) and Jeffrey Martin (1-1/8 to 5-3/4), as well as fractional drops by heavily-weighted Beecham (7/8 to 4-1/8) and Glaxo (3/8 to 15-7/8). Generic companies, led by Zenith (up 2 to 23), LyphoMed (up 1-3/4 to 22-3/4) and Mylan up (1-1/4 to 24) continued to perform strongly. Zenith is the top point gainer, with 16-1/2, among all issues during the first six months of the year. In that time period, the company's stock valuation jumped over 250% to $236 mil. (See box below). In the first half, LyphoMed's valuation is up 145% to nearly $228 mil., Par up 131.9% to $124 mil., and Reid-Provident (up 2 to 6-5/8) up 120.8% to 46.3 mil. LyphoMed's stock received a boost during the month when the firm announced the purchase of Invenex Labs from Life Technologies. Based on 1984 pro forma sales, the acquisition will create an over $60 mil. hospital generic business. During the month Reid-Provident completed a merger with Rowell Labs. Several other Pharmaceutical issues, fared well in June, including Paco (up 1-7/8 to 15-1/2) and Viratek (up 1-1/4 to 18-1/4). In its first month on the Index, Moore Medical (formerly Optel) gained 1-1/8 tp 18-5/8. The New Britain, Conn.-based whslr. began trading on the AMEX on May 23. The company, which includes the H.L. Moore Drug Exchange, had unaudited net income of $935,000 for the first quarter ended March 30 on sales of $33.0 mil. (FOOTNOTE) Charts omitted.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel